Read together with the failed fosgonimeton trial, the takeaway is that the human-relevant evidence base for this class is both thin and, where it touched humans, negative
If one provider recommends modifying your GLP-1 therapy due to eye concerns, make sure the other knows
SKQ1 SKQ1, a mitochondria-targeting antioxidant, has shown promising therapeutic potential in the treatment of various age-related eye diseases, including cataracts, AMD, glaucoma, and DE [169, 170]
This is what allows a single vial to be used across multiple preparations during a working period rather than being discarded after one access
The participants were randomly assigned to take either tirzepatide or semaglutide